coronavirus
isol
chicken
long
consid
import
pathogen
agent
anim
produc
season
cold
mild
gastrointestin
infect
human
outbreak
sever
acut
respiratori
syndrom
sar
extens
effort
went
research
specif
anticoronaviru
therapi
emerg
sar
coronaviru
sarscov
capabl
kill
peopl
month
clearli
indic
resourc
put
coronaviru
research
year
potenti
anticoronavir
compound
patent
previou
decad
coronaviru
research
author
review
publish
patentspat
applic
relev
compoundsapproach
potenti
anticoronavir
therapi
focus
approach
target
one
specif
step
coronaviru
life
cycl
like
use
lead
compound
drug
develop
case
reader
need
inform
anticoronaviru
drug
left
orphan
molecular
target
direct
excel
review
final
author
highlight
compound
like
immedi
clinic
applic
case
sar
reemerg
coronavirus
display
rather
complex
life
cycl
schematis
figur
enter
target
cell
virus
exploit
wide
varieti
cellular
receptor
transmiss
gastroenter
viru
tgev
human
coronaviru
hcov
canin
coronaviru
ccov
use
cell
membranebound
metalloproteas
aminopeptidas
n
also
refer
wide
distribut
cell
mani
tissu
includ
respiratori
enter
epitheli
neuron
glial
cell
sarscov
anoth
human
coronaviru
use
cellsurfac
zinc
peptidas
angiotensinconvert
enzym
receptor
interest
insight
viralcellular
protein
interact
uncov
crystallograph
studi
crystal
structur
ectodomain
show
clawlik
ntermin
peptidas
domain
activ
site
base
deep
groov
ctermin
collectrin
domain
spike
glycoprotein
sarscov
respons
bind
fragment
glycoprotein
region
residu
suffici
tight
bind
peptidas
domain
fragment
receptorbind
domain
rbd
critic
determin
interact
thu
viral
host
rang
tropism
crystal
structur
resolut
rbd
bound
peptidas
domain
human
recent
resolv
li
et
al
protein
data
bankpdb
access
show
rbd
present
concav
surfac
cradl
ntermin
lobe
peptidas
peptidas
domain
two
lobe
close
toward
substrat
engag
sarscov
glycoprotein
contact
tip
one
lobe
contact
lobe
occlud
peptidas
activ
site
bind
protein
alter
addit
specif
inhibitor
crystallograph
data
suggest
specif
sarscov
inhibitor
could
develop
block
protein
interact
sarscov
inhibitor
differ
inhibitor
block
peptidas
activ
inhibitor
enzymat
activ
patent
millennium
pharmaceut
inc
atom
detail
interfac
two
protein
describ
li
et
al
give
import
inform
virtual
screen
antivir
compound
alaninescan
mutagenesi
analysi
indic
charg
amino
acid
residu
import
particular
solubl
form
describ
potenti
sar
treatment
although
may
appli
decoy
neutralis
circul
virus
approach
could
hardli
find
clinic
applic
suggest
lesson
learnt
aid
research
similar
approach
use
solubl
main
receptor
postul
treatment
despit
vitro
data
encourag
solubl
found
clinic
applic
year
specif
inhibitor
interact
produc
use
isol
portion
glycoprotein
use
system
lentiviru
express
green
fluoresc
protein
pseudotyp
sarscov
glycoprotein
infect
cell
stabli
express
inventor
detect
potent
antivir
activ
peptid
compris
amino
acid
glycoprotein
nm
approach
use
peptid
order
prevent
viral
entri
encourag
result
aid
research
inde
proofofconcept
provid
system
administr
peptid
highli
conserv
region
viral
envelop
glycoprotein
significantli
impact
viral
load
easi
strategi
prevent
attach
viru
cell
use
neutralis
antibodi
monoclon
antibodi
direct
glycoprotein
sarscov
produc
antibodi
inhibit
interact
viru
strategi
may
appli
passiv
immunotherapi
immunoprophylaxi
exposit
sarscov
base
affin
antibodi
region
respons
bind
invent
might
exploit
screen
assay
antisarscov
compound
compound
bind
glycoprotein
site
interact
also
prevent
interact
antibodi
anoth
strategi
elicit
neutralis
antibodi
use
specif
vaccin
howev
descript
vaccin
strategi
would
go
beyond
scope
review
deal
therapeut
approach
anoth
group
strategi
coronavirus
aim
target
cellular
receptor
rather
viru
receptor
downmodul
postul
valuabl
approach
limit
entri
coronavirus
insid
target
cell
invent
use
doubl
singlestrand
oligomer
antisens
compound
particularli
singl
doublestrand
oligonucleotid
rna
rnalik
singlestrand
oligonucleotid
dna
dnalik
use
modul
express
aminopeptidas
n
multipl
mechan
exist
short
synthet
oligonucleotid
use
modul
gene
express
mammalian
cell
includ
degrad
rnase
h
rna
interfer
rnai
excel
review
mechan
found
advantag
approach
would
extrem
select
due
oligonucleotid
match
requir
disadvantag
would
extrem
complex
administr
molecul
furthermor
yet
known
would
effect
downmodul
human
promis
approach
limit
entri
coronaviru
target
cell
probabl
repres
old
antimalari
drug
chloroquin
advantag
small
molecul
therefor
present
difficulti
administr
past
studi
support
idea
chloroquin
might
inhibit
coronaviru
replic
cell
infect
treat
nocodazol
microtubul
depolymeris
agent
block
transport
earli
late
endosom
produc
decreas
amount
antigen
result
indic
endosom
transport
need
infect
cell
treat
chloroquin
express
decreas
amount
antigen
meanwhil
unpublish
data
obtain
author
group
show
chloroquin
potent
inhibit
replic
ccov
therapeut
achiev
concentr
figur
chloroquin
also
endow
antiinflammatori
properti
review
ii
clinic
worsen
individu
sar
week
appar
relat
immunopatholog
damag
author
suggest
chloroquin
consid
treatment
sar
test
sarscov
author
hypothesi
confirm
two
independ
vitro
studi
research
belgian
cathol
univers
leuven
found
chloroquin
inhibit
sarscov
replic
valu
within
rang
blood
concentr
achiev
antimalari
treatment
doseinduc
cytostat
activ
much
higher
timeofaddit
experi
indic
chloroquin
affect
earli
stage
sarscov
replic
research
center
diseas
control
prevent
atlanta
ga
usa
report
potent
antisarscov
effect
chloroquin
vitro
attribut
deficit
glycosyl
sarscov
receptor
antivir
drug
concentr
cytotox
result
await
confirm
anim
model
discuss
van
ranst
et
al
chloroquin
given
prophylact
peopl
travel
malariaendem
area
sar
reemerg
chloroquin
great
import
prophylact
medic
peopl
live
travel
affect
area
chloroquin
ubiquit
avail
low
cost
easi
administ
drug
gener
welltoler
may
also
administ
pregnant
women
howev
one
disadvantag
could
possibl
retinopathi
case
chronic
exposur
drug
prolong
prophylact
use
nevertheless
side
effect
revers
earli
stage
thu
prevent
regular
examin
fundu
use
quinolin
compound
includ
chloroquin
combin
multivitamin
prepar
claim
treat
differ
viral
infect
includ
caus
coronavirus
patent
disclos
invent
consist
adhes
patch
contain
essenti
oil
antimicrobi
compound
chloroquin
order
filter
kill
pathogen
coronavirus
enter
respiratori
tract
given
mechan
action
chloroquin
act
cell
rather
coronaviru
invent
result
anticoronaviru
effect
chloroquin
genom
rna
coronavirus
contain
cap
polyadenyl
singlestrand
positivesens
genom
rna
kb
length
largest
known
rna
viru
genom
coronavirusinfect
cell
contain
characterist
cotermin
nest
mrna
mrna
cap
leader
sequenc
consist
nucleotid
deriv
end
genom
nontransl
region
utr
nucleotid
follow
leader
sequenc
anoth
utr
end
rna
genom
follow
polya
tail
variabl
length
import
rna
replic
transcript
transcriptionregulatori
sequenc
typic
featur
coronavirus
short
motif
usual
near
begin
open
read
frame
orf
end
leader
sequenc
moreov
consensu
sequenc
found
immedi
front
protein
membran
protein
gene
orf
gene
organis
coronavirus
follow
pattern
gene
code
polyprotein
envelop
protein
nucleocapsid
protein
figur
group
ii
coronavirus
possess
haemagglutinin
esteras
coronaviru
genom
also
contain
varieti
addit
orf
encod
nonstructur
protein
nsp
known
function
gene
conserv
among
coronavirus
wherea
gene
encod
function
protein
directli
translat
genom
rna
product
structur
protein
requir
synthesi
specif
mrna
function
protein
figur
genom
mrna
target
rna
interfer
techniqu
describ
previou
section
use
small
interf
rna
sirna
claim
treatment
sar
human
advantag
approach
would
expectedli
low
toxic
due
extrem
select
coronaviru
inhibit
disadvantag
could
complex
administr
molecul
context
encourag
result
deriv
sarscovinfect
rhesu
macaqu
model
intranas
administr
chemic
synthesis
sirna
duplex
result
reduct
sarscov
infectioninduc
fever
ii
sarscov
viral
level
iii
acut
diffus
alveoli
damag
macaqu
show
toxic
effect
follow
cell
infect
viral
replicas
gene
fundament
genom
rna
replic
structur
protein
product
translat
directli
viral
genom
autocatalyt
process
two
type
proteas
part
replicas
polyprotein
releas
nsp
form
membranebound
rna
replic
complex
one
two
type
coronavir
proteas
proteas
resid
autocleavag
releas
downstream
replicas
subunit
respons
cleavag
polyprotein
process
site
thu
term
main
proteas
wherea
coronavir
plpro
cleav
three
ntermin
polyprotein
process
site
thu
term
accessori
proteas
cystein
proteas
activ
site
sarscov
form
catalyt
dyad
cystein
proteas
usual
display
catalyt
triad
consist
serin
histidin
aspart
howev
structur
sarscov
show
aspart
residu
vicin
sarscov
homodim
monom
compris
three
domain
first
two
domain
show
chymotrypsinlik
fold
root
mean
squar
deviat
bovin
fold
first
two
domain
respons
catalyt
reaction
wherea
third
domain
play
critic
role
enzym
dimeris
chymotrypsinlik
fold
intrigu
overal
sequenc
ident
quit
low
chymotrypsinfold
rais
hypothesi
origin
chymotrypsinlik
serin
proteas
later
evolv
cystein
proteas
potenti
use
drug
target
support
fundament
role
coronaviru
replic
ii
well
defin
structur
iii
preliminari
clinic
observ
indic
drug
crosstarget
enzym
proteas
inhibitor
pi
produc
clinic
benefit
patient
treat
ifn
ribavirin
thoroughli
studi
group
drug
target
repres
pi
clinic
virolog
biochem
bioinformat
data
concur
suggest
main
target
anticoronavir
effect
pi
although
robust
data
provid
causal
link
inhibit
impair
sarscov
replic
still
lack
stori
pi
potenti
sar
treatment
began
sar
outbreak
empir
administr
affect
individu
antiretrovir
prepar
kaletra
abbott
contain
lopinavir
ritonavir
ratio
ww
retrospect
match
cohort
studi
chan
et
al
found
addit
lopinavirritonavir
standard
initi
treatment
protocol
associ
reduct
overal
death
rate
intub
rate
compar
match
cohort
receiv
standard
treatment
respect
p
lower
necess
methylprednisolon
high
dose
anoth
studi
chu
et
al
evalu
effect
kaletra
associ
ribavirin
drug
caus
mutat
rna
mani
virus
advers
clinic
outcom
acut
respiratori
distress
syndrom
death
significantli
lower
treatment
group
histor
control
treat
ribavirin
alon
versu
p
day
onset
symptom
clinic
effect
antiretrovir
drug
sar
initi
attribut
nonspecif
antiinflammatori
effect
vitro
studi
later
show
member
pi
class
could
inde
exert
direct
antivir
effect
sarscov
pi
nelfinavir
ritonavir
significantli
effici
inhibit
viral
antigen
express
measur
immunofluoresc
product
virion
measur
realtim
revers
transcriptasepolymeras
chain
reaction
rtpcr
cytopath
effect
measur
methyl
tetrazolium
assay
vero
cell
infect
sarscov
multipl
infect
moreov
timeofaddit
experi
show
nelfinavir
inhibit
sarscov
replic
postentri
step
lopinavir
inhibit
cytopath
effect
sarscov
measur
plaquereduct
assay
fetal
rhesu
cell
note
effect
lopinavir
synergist
ribavirin
drug
shown
otherwis
ineffect
treatment
sar
therefor
chu
et
al
attribut
antivir
synerg
clinic
benefit
observ
individu
sar
treat
ribavirin
plu
kaletra
chen
et
al
screen
effect
differ
antivir
compound
ten
clinic
isol
sarscov
compound
includ
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
stavudin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
pi
ritonavir
lopinavir
lopinavir
result
exert
detect
effect
sarscov
valu
lopinavir
rang
h
postinfect
respect
cell
line
howev
warn
antivir
effect
variabl
cell
linedepend
exampl
valu
lopinavir
prototyp
sarscov
strain
rang
cell
vero
cell
therefor
like
antivir
effect
antisar
compound
report
literatur
exagger
underestim
depend
assay
cell
line
use
differ
group
regard
exampl
ribavirin
interest
report
inhibitor
sarscov
replic
wherea
other
report
exert
antivir
effect
concentr
high
reach
vivo
latter
view
also
support
clinic
data
limit
experiment
evid
avail
inhibitori
effect
pi
support
comput
simul
reveal
catalyt
site
allow
dock
sever
pi
clinic
use
pi
partial
fill
bind
caviti
recent
bioinformat
studi
indic
stabl
interact
among
three
wellknown
pi
indinavir
saquinavir
ritonavir
ritonavir
found
display
signific
hydrogen
bond
observ
line
previou
calcul
group
use
sarscov
tgev
among
variou
compound
test
zhang
et
al
indic
ritonavir
compound
highest
bind
affin
ki
x
author
attribut
kaletra
compon
lopinavir
ki
valu
x
instead
enwitheesuk
et
al
attribut
ki
valu
ritonavir
recent
calcul
attribut
ki
valu
ritonavir
ki
valu
realist
previous
report
given
pi
highest
concentr
test
ie
determin
inhibit
proteas
partial
one
advantag
pi
among
drug
clinic
evid
potenti
use
treatment
sar
provid
although
still
limit
randomis
trial
would
need
valid
result
sar
return
disadvantag
kaletra
might
found
advers
effect
lipid
metabol
high
cost
molecul
patent
specif
devot
claim
use
pi
sarscov
inhibitor
howev
one
previous
quot
patent
claim
use
inhal
differ
compound
includ
princip
pi
differ
respiratori
infect
caus
coronavirus
administr
compound
inhal
allow
achiev
local
drug
concentr
suffici
inhibit
viral
replic
avoid
system
side
effect
peptid
inhibitor
develop
differ
peptid
inhibitor
compound
describ
togeth
procedur
synthesi
publish
applic
describ
method
synthesi
sarscov
inhibitor
biolog
data
activ
compound
sarscov
also
suppli
compound
found
valu
valu
gave
select
index
si
compound
exampl
found
valu
valu
suggest
potenti
high
therapeut
index
compound
inhibit
cytopath
effect
sarscov
detect
toxic
cell
cultur
two
compound
data
inhibit
viral
cytopath
effect
provid
compound
inhibit
cytopath
effect
sarscov
wherea
compound
inhibit
enough
data
avail
group
drug
draw
conclus
howev
vitro
data
seem
encourag
base
structur
similar
proteas
rhinovirus
coronavir
use
rhinoviru
inhibitor
compound
sarscov
propos
pfizer
agouron
pharmaceut
compound
contain
ethylacryl
ester
moieti
termin
warhead
thu
act
michael
acceptor
accord
dock
studi
conduct
inventor
nucleophil
carbon
posit
coval
bind
activ
site
sarscov
thu
inactiv
irrevers
michael
acceptor
inhibitor
describ
pfizer
patent
applic
similar
compound
claim
agouron
pharma
although
inventor
describ
procedur
test
compound
infect
cell
cultur
molecular
dock
data
provid
inhibitor
present
acryl
group
describ
includ
natur
substanc
name
cinanserin
gener
nucleophil
proteas
inhibitor
due
theoret
capac
coval
inactiv
expect
potent
inhibit
sarscov
vivo
howev
safeti
molecul
care
test
cell
cultur
anim
model
given
potenti
toxic
nucleophil
molecul
miscellan
inhibitor
describ
dicycl
multicycl
compound
molecul
present
backbon
chemic
divers
molecul
earli
phase
test
allow
conclus
drawn
invent
describ
boroncontain
inhibitor
inhibitor
possibl
proteas
inhibitor
may
backbon
wherein
moieti
h
differ
substitu
includ
aromat
cyclic
compound
heterocycl
x
u
variou
linker
group
q
repres
differ
moieti
includ
keton
alkan
alken
cyclic
compound
inventor
chose
use
boroncontain
compound
inhibit
coronaviru
base
use
boric
acid
variou
boron
acid
inhibitor
proteas
common
capac
hydrolys
amid
bond
compound
effect
inhibit
enzymat
assay
biolog
data
infect
cell
provid
earli
draw
conclus
particular
molecul
use
boroncontain
compound
inhibit
viral
proteas
seem
interest
light
recent
crystallograph
data
use
proteas
process
aminoproxim
nsp
carri
one
two
paralog
proteas
domain
within
largest
nsp
defin
homolog
papainlik
fold
constitut
peptidas
famili
although
mutat
analys
support
presenc
cyshi
catalyt
dyad
clear
enzym
also
catalyt
triad
cyshisasp
coronavirus
harbor
two
papainlik
proteas
sequenc
plpro
wherea
scov
avian
infecti
bronchiti
coronaviru
ibv
utilis
one
equival
may
cleav
upstream
upstream
cleavag
associ
actual
fact
coronavir
plpro
although
built
common
papainlik
scaffold
look
structur
like
ubuquitinspecif
proteas
usp
merop
famili
like
papain
merop
famili
coronavir
plpro
twodomain
organis
circularli
permut
znfinger
domain
nest
middl
papainlik
fold
precis
case
usp
plpro
recent
shown
possess
deubiquitinyl
activ
might
mean
coronavir
protein
may
escap
proteasom
degrad
pathway
thu
limit
antigen
present
hla
class
molecul
avoid
immun
respons
recent
observ
strengthen
hypothesi
plpro
may
import
drug
target
therapeut
intervent
although
substanc
inhibit
sarscov
plppro
describ
patent
patent
applic
publish
yet
search
engin
consult
hope
recent
resolut
structur
help
develop
new
effect
inhibitor
coronaviru
replic
interestingli
zinc
ion
inhibit
proteas
activ
potent
valu
inhibit
specif
dival
metal
mg
mn
ca
ni
co
effect
activ
sarscov
data
shown
therefor
plpro
inhibitor
patent
futur
like
contain
zinc
one
protein
releas
proteolyt
activ
main
proteas
act
rnadepend
rna
polymeras
rdrp
coronavir
rdrp
catalys
product
new
fulllength
genom
rna
packag
virion
well
nest
set
monocistron
mrna
encod
structur
protein
activ
requir
format
intermedi
negativesens
rna
figur
due
pivot
role
viral
rna
synthesi
consequ
protein
synthesi
genom
duplic
kda
rdrp
repres
attract
target
antisar
therapi
howev
lack
structur
biochem
inform
coronaviru
rdrp
structur
predict
complic
fact
coronaviru
rdrp
significantli
diverg
cellular
viral
rna
polymeras
recent
structur
model
built
catalyt
domain
sarscov
rdrp
model
provid
first
insight
activ
site
protein
also
enabl
conclus
drawn
properti
potenti
nucleosid
analogueinhibitor
coronaviru
rdrp
thu
propos
potenti
nucleosid
analogueinhibitor
contain
group
posit
capabl
make
hydrogen
bond
interact
rdrp
residu
clearli
direct
structur
inform
highli
desir
develop
effect
inhibitor
key
enzym
patent
applic
claim
use
aurintricarboxyl
acid
ata
inhibitor
sarscov
rdrp
accord
inventor
ata
inhibit
sarscov
replic
vero
cell
mgml
mgml
signific
inhibit
glycoprotein
product
observ
sarscovinfect
cell
treat
ata
result
inhibit
viral
protein
synthesi
detect
toxic
observ
uninfect
vero
cell
treat
similar
concentr
ata
howev
ata
quit
nonspecif
inhibitor
differ
dnarna
polymeras
thu
potenti
use
ata
per
se
consid
caution
given
past
experi
test
compound
integras
inhibitor
despit
initi
encourag
result
compound
abandon
due
insuffici
specif
integras
inhibit
case
coronavirus
research
compound
abandon
given
pauciti
report
rdrp
inhibitor
exampl
ata
could
serv
valuabl
lead
develop
specif
inhibitor
coronavir
rdrp
sarscov
rdrp
could
also
inhibit
oligonucleotid
mimic
thereof
appropri
sequenc
base
indic
bx
follow
structur
formula
may
creat
regular
oligonucleotid
oligonucleotidelik
molecul
oligonucleotidelik
molecul
might
multipl
applic
modifi
oligonucleotid
mimic
design
prevent
degrad
rnase
come
contact
viral
rna
increas
hybridis
properti
lipophil
last
properti
facilit
transit
molecul
plasma
membran
modif
aim
prevent
degrad
rnase
includ
revers
protect
oxygen
substitu
posit
dicycl
substitu
ribos
increas
bind
properti
target
rna
use
tricycl
heterocycl
moieti
compound
taken
account
peptid
nucleic
acid
use
uncharg
amid
bond
instead
phosphat
diester
link
adjac
ribos
could
increas
hybridis
properti
also
facilit
passag
molecul
cellular
membran
morpholinobas
oligomer
compound
nonion
mimic
oligonucleotid
like
pass
cellular
membran
less
like
form
complex
protein
compar
oligonucleotid
counterpart
invent
take
account
use
cyclohexenyl
nucleic
acid
cena
molecul
gener
formula
compound
furanos
ring
replac
cyclohexenyl
ring
gener
incorpor
cena
monom
dna
chain
increas
stabil
dnarna
hybrid
apart
potenti
rnai
strategi
molecul
might
use
form
complex
viral
positivesens
rna
thu
hinder
transcriptiondupl
inventor
awar
potenti
difficulti
system
administr
molecul
consid
inhal
rout
possibl
way
administ
molecul
human
anoth
protein
releas
proteolyt
activ
hel
specif
unwind
polynucleotid
duplex
polar
hel
sarscov
similar
properti
polar
unwind
stimul
atpas
activ
singlestrand
polynucleotid
abil
hel
hydrolys
wide
varieti
ribonucleosidetriphosph
ntp
deoxyribonucleosidetriphosph
dntp
consist
triphosph
moieti
form
basi
recognit
factor
bind
hydrolysi
possibl
lack
select
ntp
hydrolysi
also
enabl
helicas
act
broad
rna
viral
cap
basal
atpas
activ
coronavir
helicas
stimul
polynucleotid
except
poli
g
poli
dg
signific
variat
strength
homopolynucleotid
bind
report
suggest
sarscov
helicas
may
possess
element
secondari
structuresequ
recognit
capabl
hypothesis
specif
may
play
role
localis
put
complex
select
genom
locat
subgenom
rna
synthesi
augment
propos
basepair
factor
direct
unwind
suggest
helicas
may
aid
replic
process
disrupt
secondari
structur
displac
bound
protein
anneal
rna
fragment
put
role
requir
experiment
valid
coronavir
hel
possess
cysteinrich
put
metal
bind
domain
ntermin
portion
form
mutat
analysi
relat
equin
anaemia
viru
implic
subgenom
mrna
synthesi
genom
replic
virion
biogenesi
hel
thought
essenti
nidoviru
viabil
therefor
potenti
target
develop
antisar
drug
interestingli
hel
report
inhibit
adamantinepyridox
conjug
bananin
unfortun
author
found
publish
patent
patent
applic
regard
compound
search
engin
consult
case
specif
patent
exist
bananin
may
serv
valuabl
lead
compound
patent
hel
inhibitor
mani
compound
possibl
anticoronaviru
activ
research
especi
major
sar
outbreak
compound
deserv
particular
attent
drug
alreadi
regist
use
human
drug
includ
antimalari
chloroquin
pi
antihelmynth
compound
niclosamid
one
drug
howev
molecular
target
defin
yet
drug
wellknown
longstudi
toxic
profil
repres
interest
compound
might
immedi
test
clinic
trial
case
sar
reemerg
claim
cover
patent
contain
novel
interest
applic
exist
drug
includ
drug
administr
inhal
rout
administr
could
cours
reduc
system
side
effect
drug
allow
increas
local
concentr
increas
local
concentr
could
particularli
import
anticoronaviru
use
drug
design
diseas
condit
exist
patent
probabl
allow
industri
develop
new
way
administ
old
drug
hand
patentsappl
use
promis
compound
chloroquin
pi
coronaviru
infect
cover
possibl
applic
use
chloroquin
pi
cover
exist
patentsappl
drug
might
sold
lower
price
could
particular
interest
resourcepoor
countri
chloroquin
use
prophylact
weapon
resid
travel
sarsaffect
area
encourag
severaldecad
long
use
drug
antimalari
prophylaxi
author
knowledg
cover
patent
goe
use
pi
system
treatment
coronaviru
infect
note
potenti
chloroquin
provid
prolong
prophylaxi
uniqu
among
differ
investig
drug
addit
mani
patent
cover
use
brand
new
agent
inhibit
valid
drug
target
within
coronaviru
life
cycl
compound
possibl
repres
new
therapeut
weapon
prove
satisfactori
toxic
profil
suffici
anticoronaviru
activ
anim
model
altern
may
repres
interest
drug
lead
note
patent
patent
applic
publish
yet
potenti
inhibitor
plppro
helicas
enzym
seem
novel
extrem
interest
drug
target
due
multipl
function
necessari
near
futur
fill
gap
develop
specif
inhibitor
final
lesson
choic
best
antivir
strategi
learnt
success
failur
quartercenturi
research
anoth
viral
infect
